Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression

Oncogene

Volumn 35, Issue 39, 2016, Pages 5170-5178

  Black, S A ^a   Nelson, A C ^b   Gurule, N J ^a,c   Futscher, B W ^d,e   Lyons, T R ^a,c,f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN RECEPTOR; COLLAGEN; CYCLOOXYGENASE 2; INTEGRIN RECEPTOR; SEMAPHORIN; SEMAPHORIN 7A; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; PTGS2 PROTEIN, HUMAN; SEMA7A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; DISEASE COURSE; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL MOVEMENT; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PLEIOTROPY; GPI-LINKED PROTEINS; HUMANS; LYMPHANGIOGENESIS; MAMMARY NEOPLASMS, ANIMAL; MICE; SEMAPHORINS; SIGNAL TRANSDUCTION;

EID: 84963502606     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.49     Document Type: Article

References (35)

1. Pasterkamp RJ, Kolk SM, Hellemons AJ, Kolodkin AL. Expression patterns of semaphorin7A and plexinC1 during rat neural development suggest roles in axon guidance and neuronal migration. BMC. Dev Biol 2007; 7: 98.
2. Pasterkamp RJ, Kolodkin AL. Semaphorin junction: making tracks toward neural connectivity. Curr Opin Neurobiol 2003; 13: 79-89.
3. Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 2003 24; 424: 398-405.
4. Adams RH, Eichmann A. Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol 2010; 2: a001875.
5. Garcia-Areas R, Libreros S, Amat S, Keating P, Carrio R, Robinson P et al. Semaphorin7A promotes tumor growth and exerts a pro-angiogenic effect in macrophages of mammary tumor-bearing mice. Front Physiol 2014; 5: 17.
6. Gelfand MV, Hong S, Gu C. Guidance from above: common cues direct distinct signaling outcomes in vascular and neural patterning. Trends Cell Biol 2009; 19: 99-110.
7. Gu C, Giraudo E. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res 2013; 319: 1306-1316.
8. Ghanem RC, Han KY, Rojas J, Ozturk O, Kim DJ, Jain S et al. Semaphorin 7A promotes angiogenesis in an experimental corneal neovascularization model. Curr Eye Res 2011; 36: 989-996.
9. Scott GA, McClelland LA, Fricke AF. Semaphorin 7a promotes spreading and dendricity in human melanocytes through beta1-integrins. J Invest Dermatol 2008; 128: 151-161.
10. Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takegahara N, Takamatsu H et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature 2007; 446: 680-684.
11. Delorme G, Saltel F, Bonnelye E, Jurdic P, Machuca-Gayet I. Expression and function of semaphorin 7A in bone cells. Biol Cell 2005; 97: 589-597.
12. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015; 1: 888-896.
13. Maurin JC, Delorme G, Machuca-Gayet I, Couble ML, Magloire H, Jurdic P et al. Odontoblast expression of semaphorin 7A during innervation of human dentin. Matrix Biol 2005; 24: 232-238.
14. Czopik AK, Bynoe MS, Palm N, Raine CS, Medzhitov R. Semaphorin 7A is a negative regulator of T cell responses. Immunity 2006; 24: 591-600.
15. Koh JM, Oh B, Lee JY, Lee JK, Kimm K, Kim GS et al. Association study of semaphorin 7a (sema7a) polymorphisms with bone mineral density and fracture risk in postmenopausal Korean women. J Hum Genet 2006; 51: 112-117.
16. Moserle L, Casanovas O. Exploiting pleiotropic activities of semaphorins as multitarget therapies for cancer. EMBO Mol Med 2012; 4: 168-170.
17. Allegra M, Zaragkoulias A, Vorgia E, Ioannou M, Litos G, Beug H et al. Semaphorin-7a reverses the ERF-induced inhibition of EMT in Ras-dependent mouse mammary epithelial cells. Mol Biol Cell 2012; 23: 3873-3881.
18. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PloS One 2011; 6: e17911.
19. Behbod F, Kittrell FS, Lamarca H, Edwards D, Kerbawy S, Heestand JC et al. An intra-ductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 2009; 11: R66.
20. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000; 92: 1185-1186.
21. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer 2007; 120: 2127-2134.
22. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13: 394-406.
23. Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 2011; 17: 1109-1115.
24. Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ. p63 expression in benign and malignant breast lesions. Histol Histopathol 2004; 19: 465-471.
25. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002; 9: 216-219.
26. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113-1120.
27. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
28. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
29. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
30. Lyons TR, Borges VF, Betts CB, Guo Q, Kapoor P, Martinson HA et al. Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. J Clin Invest 2014; 124: 3901-3912.
31. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelialstromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA 2009; 106: 3372-3377.
32. Maller O, Hansen KC, Lyons TR, Acerbi I, Weaver VM, Prekeris R et al. Collagen architecture in pregnancy-induced protection from breast cancer. J Cell Sci 2013; 126(Pt 18): 4108-4110.
33. Esserman L, Yau C. Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 2015; 1: 881-883.
34. Formolo CA, Williams R, Gordish-Dressman H, MacDonald TJ, Lee NH, Hathout Y. Secretome signature of invasive glioblastoma multiforme. J Proteome Res 2011; 10: 3149-3159.
35. Aslakson CJ, Rak JW, Miller BE, Miller FR. Differential influence of organ site on three subpopulations of a single mouse mammary tumor at two distinct steps in metastasis. Int J Cancer 1991; 47: 466-472.